Positive News SentimentPositive NewsNASDAQ:BDTX Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis $2.75 -0.10 (-3.51%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.80 +0.05 (+1.82%) As of 08/29/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Black Diamond Therapeutics Stock (NASDAQ:BDTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BDTX alerts:Sign Up Key Stats Today's Range$2.69▼$2.8550-Day Range$2.27▼$3.2152-Week Range$1.20▼$6.37Volume563,573 shsAverage Volume864,501 shsMarket Capitalization$156.57 millionP/E Ratio11.96Dividend YieldN/APrice Target$12.40Consensus RatingBuy Company Overview Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Read More Black Diamond Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreBDTX MarketRank™: Black Diamond Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 348th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingBlack Diamond Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBlack Diamond Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Black Diamond Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Black Diamond Therapeutics are expected to grow in the coming year, from ($1.30) to ($1.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Black Diamond Therapeutics is 11.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 270.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Black Diamond Therapeutics is 11.96, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.19.Price to Book Value per Share RatioBlack Diamond Therapeutics has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Black Diamond Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.10% of the float of Black Diamond Therapeutics has been sold short.Short Interest Ratio / Days to CoverBlack Diamond Therapeutics has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Black Diamond Therapeutics has recently increased by 6.93%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBlack Diamond Therapeutics does not currently pay a dividend.Dividend GrowthBlack Diamond Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.10% of the float of Black Diamond Therapeutics has been sold short.Short Interest Ratio / Days to CoverBlack Diamond Therapeutics has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Black Diamond Therapeutics has recently increased by 6.93%, indicating that investor sentiment is decreasing significantly. News and Social Media4.2 / 5News Sentiment1.57 News SentimentBlack Diamond Therapeutics has a news sentiment score of 1.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.11 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Black Diamond Therapeutics this week, compared to 2 articles on an average week.Search Interest12 people have searched for BDTX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows6 people have added Black Diamond Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Black Diamond Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.97% of the stock of Black Diamond Therapeutics is held by insiders.Percentage Held by Institutions95.47% of the stock of Black Diamond Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Black Diamond Therapeutics' insider trading history. Receive BDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BDTX Stock News HeadlinesBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of "Buy" from AnalystsAugust 30 at 2:28 AM | americanbankingnews.comBlack Diamond Therapeutics: A Potential First-Line In NSCLC Trading At CashAugust 25, 2025 | seekingalpha.comThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening RIGHT NOW—this project is poised to see massive moves.... The smart money is already positioning.September 1 at 2:00 AM | Crypto 101 Media (Ad)Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?August 9, 2025 | finance.yahoo.comBlack Diamond Therapeutics, Inc: Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 9, 2025 | finanznachrichten.deBlack Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 7, 2025 | globenewswire.comBlack Diamond Therapeutics, Inc. (BDTX) Rated Outperform as Lead Drug Shows PromiseJuly 15, 2025 | msn.comBlack Diamond Therapeutics Inc. BDTX (U.S.: Nasdaq) - The Wall Street JournalJune 25, 2025 | wsj.comSee More Headlines BDTX Stock Analysis - Frequently Asked Questions How have BDTX shares performed this year? Black Diamond Therapeutics' stock was trading at $2.14 at the start of the year. Since then, BDTX stock has increased by 28.5% and is now trading at $2.75. How were Black Diamond Therapeutics' earnings last quarter? Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) issued its quarterly earnings results on Thursday, August, 7th. The company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.06. When did Black Diamond Therapeutics IPO? Black Diamond Therapeutics (BDTX) raised $151 million in an IPO on Thursday, January 30th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Black Diamond Therapeutics' major shareholders? Top institutional investors of Black Diamond Therapeutics include Marshall Wace LLP (1.30%), Geode Capital Management LLC (0.87%), Jane Street Group LLC (0.37%) and XTX Topco Ltd (0.31%). Insiders that own company stock include Ali Behbahani, Growth N V Biotech and David M Epstein. View institutional ownership trends. How do I buy shares of Black Diamond Therapeutics? Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Black Diamond Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Black Diamond Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Toast (TOST), Meta Platforms (META) and Luminar Technologies (LAZR). Company Calendar Last Earnings8/07/2025Today9/01/2025Next Earnings (Estimated)11/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BDTX CIK1701541 WebN/A Phone617-252-0848FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Price Target for Black Diamond Therapeutics$12.40 High Price Target$15.00 Low Price Target$10.00 Potential Upside/Downside+350.9%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$0.23 Trailing P/E Ratio11.96 Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.68 million Net MarginsN/A Pretax Margin20.63% Return on Equity12.70% Return on Assets9.58% Debt Debt-to-Equity RatioN/A Current Ratio8.73 Quick Ratio8.73 Sales & Book Value Annual Sales$70 million Price / Sales2.24 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book1.87Miscellaneous Outstanding Shares56,935,000Free Float53,536,000Market Cap$156.57 million OptionableOptionable Beta2.93 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:BDTX) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.